Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26972530 | 1.00 | DRD3 (0.49) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL24508777 | 1.00 | DRD3 (0.49) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL22463774 | 0.88 | SIGMAR1 (0.52) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL14027741 | 0.88 | SIGMAR1 (0.52) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL29645051 | 0.88 | SIGMAR1 (0.52) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL22463763 | 0.86 | EBP (0.59) | DRD3KDM1APDK1DRD1EBP | |
| SCHEMBL22463780 | 0.85 | EBP (0.62) | DRD3KDM1ADRD1EBPSIGMAR1 | |
| SCHEMBL4242387 | 0.85 | EBP (0.62) | DRD3KDM1ADRD1EBPSIGMAR1 | |
| SCHEMBL6712360 | 0.85 | EBP (0.62) | DRD3KDM1ADRD1EBPSIGMAR1 | |
| SCHEMBL6833201 | 0.85 | EBP (0.62) | DRD3KDM1ADRD1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227234-B1 | SILICOALUMINOPHOSPHATE MOLECULAR SIEVES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC (US) | 2021-05-26 | — | — | EP | claimed |
| US-20180258058-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2018-09-13 | — | — | US | claimed |
| US-9815706-B2 | Zeolites using an organo-1-oxa-4-azoniumcyclohexane compound | UOP LLC (US) | 2017-11-14 | — | — | US | claimed |
| EP-3227266-A2 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2017-10-11 | — | — | EP | claimed |
| US-9751772-B2 | Aluminophosphate molecular sieves using an organo-1-oxa-4-azoniumcyclohexane compound | UOP LLC (US) | 2017-09-05 | — | — | US | claimed |
| US-20170044120-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2017-02-16 | — | — | US | claimed |
| US-9522896-B2 | Organo-1-oxa-4-azonium cyclohexane compounds | UOP LLC (US) | 2016-12-20 | — | — | US | claimed |
| US-20160159656-A1 | ALUMINOPHOSPHATE MOLECULAR SIEVES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC | 2016-06-09 | — | — | US | claimed |
| US-20160159760-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC | 2016-06-09 | — | — | US | claimed |
| US-20160159655-A1 | ZEOLITES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC | 2016-06-09 | — | — | US | claimed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023066292-A1 | TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021226517-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2013036684-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011109657-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159760-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | OXSR1, OXER1, OCIAD1 | DRD3 937/4885KDM1A 232/4885PDK1 1344/4885 |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | DRD3 2616/4885KDM1A 3542/4885PDK1 1550/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | DRD3 3416/4885KDM1A 1766/4885PDK1 1358/4885 |
| US-20180258058-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | OXSR1, OXER1, OCIAD1 | DRD3 937/4885KDM1A 232/4885PDK1 1344/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | DRD3 2733/4885KDM1A 2863/4885PDK1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.